In addition to viral and environmental/behavioural factors, host genetic diversity is believed to contribute to the spectrum of clinical outcomes in hepatitis C virus (HCV) infection. This paper reviews the literature with respect to studies of host genetic determinants of HCV outcome and attempts to highlight trends and synthesise findings. With respect to the susceptibility to HCV infection, several studies have replicated associations of the HLA class II alleles DQB1*0301 and DRB1*11 with selflimiting infection predominantly in Caucasian populations. Meta-analyses yielded summary estimates of 3.0 (95% CI: 1.8-4.8) and 2.5 (95% CI: 1.7-3.7) for the effects of DQB1*0301 and DRB1*11 on self-limiting HCV, respectively. Studies of genetics and the response to interferon-based therapies have largely concerned single-nucleotide polymorphisms and have been inconsistent. Regarding studies of genetics and the progression of HCV-related disease, there is a trend with DRB1*11 alleles and less severe disease. Studies of extrahepatic manifestations of chronic HCV have shown an association between DQB1*11 and DR3 with the formation of cryoglobulins. Some important initial observations have been made with respect to genetic determinants of HCV outcome. Replication studies are needed for many of these associations, as well as biological data on the function of many of these polymorphisms.
Introduction
Hepatitis C virus (HCV) infection is characterised by a spectrum of outcomes. Asymptomatic in the vast majority of individuals, transition from acute to chronic infection is usually without notice. 1 Studies have suggested susceptibility to HCV infection is variable, with approximately 54-86% of individuals infected with HCV developing persistent (chronic) infections. Women and individuals infected at a younger age have lower rates of chronicity. [2] [3] [4] Among those chronically infected, some individuals develop cirrhosis or liver cancer (hepatocellular carcinoma), while others experience little progression. 1, 5, 6 Some individuals with chronic HCV develop a number of extrahepatic comorbidities, ranging from autoimmune manifestations to disorders such as diabetes. [7] [8] [9] [10] A geographic gradient with respect to autoimmune manifestations in HCV may exist. For example, the presence of cryoglobulins and autoantibodies is largely a southern European phenomenon. 11, 12 Therapy for chronic HCV infection has greatly improved. Newer regimens such as pegylated interferon-a in combination with ribavirin result in viral eradication in approximately 50% of individuals with genotype-1 infections and 70% of those with non-1 type infections. 13, 14 In addition to viral (ie, viral genotypes) and environmental/behavioural factors (ie, coinfections or excessive alcohol intake), host genetic factors are believed to exert an impact on the outcome of HCV infection. Studies among monozygotic twins suggest that host genetic factors may account for 50% or more of the variability in the major outcomes in infectious diseases. 15 This paper reviews the published literature on genetic factors and HCV outcome. For the purpose of conciseness, the present review will only focus on studies examining the genetic determinants of susceptibility to HCV infection, response to interferon therapy, presence of comorbidities (extrahepatic manifestations), and progression or severity of HCV and excludes studies concerning liver transplantation-related and statistical issues in genetic association studies.
Results
Among papers identified using the present search parameters, 107 were disease association studies that directly pertained to the topic of genetics and the susceptibility to HCV infection, the response to therapy, progression of HCV infection or extrahepatic manifestations.
Susceptibility to persistent HCV infection
A total of 37 studies address susceptibility to HCV infection. Major histocompatability complex (MHC) gene products encode key components of the antigen presentation and processing pathways and have been the focus of many studies. 53 Several consistent associations have been observed with specific MHC alleles and the susceptibility to HCV, and are highlighted in Table 1 .
A number of studies in several populations have reported an association between DQB1*0301 and viral clearance. 4, 16, 17, 25, 32, 35, 39, 41, 52 One study, however, reported an opposite effect for DQB1*0301. 48 Several of these studies on susceptibility to HCV compared individuals with chronic HCV infection to healthy controls. The use of healthy individuals poses a study design problem, as an estimated 54-86% of these controls, if exposed to the HCV, would develop chronic infections, while the others experience viral clearance. Ideally, individuals with documented self-limiting infections (anti-HCV antibody positive, but PCR negative for HCV-RNA) should be compared to individuals with chronic infections (anti-HCV antibody and HCV-RNA positive). One of the most convincing features of the possible role of DQB1*0301 in self-limiting HCV infection is the fact that this allele, along with different extended haplotypes, has been correlated with acute infection in several populations. A French study correlated the DRB1*1101-DQA1*0501-DQB1*0301 haplotype with HCV clearance. 16 A British study found that the DRB1*0401-DQA1*03-DQB1*0301 haplotype correlated with clearance. 25 In Italy, two studies have shown an association for DRB1*1104-DQB1*0301 with self-limiting HCV as well. 32, 52 The association of the DQB1*0301 allele with self-limiting HCV in the presence of different DRB1 alleles suggests that this particular allele may play an important role in the natural clearance of HCV viraemia. 54 Another allele that has been correlated with selflimiting HCV is DRB1*1101. 16, 17, 35, 39, 50 An Italian study found a protective role for the DR5 sero-group against HCV infection. 51 The molecularly-defined DRB1*1100 and DRB1*1200 groups of alleles are part of the serologically defined DR5 group. The DRB1*1101 allele was also correlated with susceptibility to vertically transmitted HCV infection. 33 To examine the associations between DQB1*0301 and the DRB1*1101 alleles and self-limiting HCV more closely, a meta-analysis employing data from the published literature was conducted. 55 To ensure that similar studies were pooled, only studies examining DQB1*0301 that employed molecular genotyping techniques and compared those with self-limiting infections (HCV antibody positive, but PCR negative) to those with chronic infections (HCV antibody positive and HCV-RNA PCR positive) were employed. Only data involving Caucasian individuals were utilised in the analysis.
Because many studies involving the DR locus only reported alleles to their two-digit specificities, studies reporting four-digit allele specificities were collapsed into their respective two-digit categories and all metaanalyses were conducted with these data. In other words, all alleles such as DRB1*1101, DRB1*1103, etc. were grouped together as DRB1*11. Similar to the analysis of DQB1*0301 above, only those studies of Caucasian individuals employing molecular genotyping techniques that compared those with self-limiting infections to those with chronic infection were included. Figure 1 presents the results of these meta-analyses. Figure 1a presents the data for DQB1*0301, while Figure 1b presents the data for DRB1*11.
It is important to note that the identification of individuals with self-limiting infections has largely been retrospective in nature. Measurement of potential confounding factors such as viral genotypes and the dose of virus in a retrospective setting have been difficult or impossible in most cases.
The analysis of DQB1*0301 and self-limiting infection shows a summary estimate of 3.0 (95% CI: 1.8-4.8) (Figure 1a ). Statistical analyses suggests that considerable heterogeneity exists with respect to the studies of DQB1*0301 and viral clearance (Q ¼ 21.1; P ¼ 0.004). Sensitivity analysis suggested that the study by Fanning in 2000 contributed most to the statistical heterogeneity observed. Without this study, the observed heterogeneity is greatly reduced (Q ¼ 7.768; P ¼ 0.169; summary estimate ¼ 3.574 (95% CI: 2.398-5.328)). Studies of DRB1*11 and self-limiting infection are less heterogeneous (Q ¼ 6.9; P ¼ 0.503). The summary estimate for the effect of DRB1*11 on self-limiting infection is 2.5 (95% CI: 1.7-3.7). The studies involving DRB1*11 are generally smaller in size and have less precision (Figure 1b) .
These meta-analyses must be interpreted with caution. To avoid excess heterogeneity, only studies that fulfilled specific criteria were included. Considerable publication and investigator-submission biases exist. Many studies showing no association between class II alleles and selflimiting infection may not be in the published literature both because journals tend to dislike publication of negative studies and/or many investigators do not bother writing-up negative results. Also, some negative studies may eventually be published in non-English journals, which were not targeted in this review.
A situation exists in Ireland where a number of women were infected with HCV by contaminated RhD immunoglobulin. 56 The viral strain of the infecting inoculum and the dose were consistent in this outbreak. An association has been reported for HLA-DRB1*0101 with self-limiting infection in this cohort. 19, 26 Thio et al 41 also observed an effect for DRB1*0101.
Few studies were found that examine MHC class I genes and the outcome of HCV. Thio et al 42 Although most association studies of genetic susceptibility to HCV infection have involved the MHC, several studies have also addressed the potential role of non-MHC loci. One of the more interesting stories concerns the potential role of the chemokine receptor (CCR5) in resistance to HCV infection. 49 CCR5 has gained considerable attention in the past few years because of its role as a coreceptor for the human immunodeficiency virus (HIV). Homozygotes for a deletion variant (CCR5*D32) are conferred a relatively high resistance to HIV infection. Although CCR5's role as a coreceptor for HIV is clearly not directly relevant to HCV infection, CCR5 is the principal ligand for several chemokines: macrophage inflammatory protein (MIP)-1a, MIP-1b and RANTES. Because chemokines and chemokine receptors are important in lymphocyte recruitment, it is possible that the CCR5*D32 variant may influence the outcome of other infections, such as HCV, via this pathway. In a study conducted among haemophiliacs by Woitas and colleagues, a higher than expected frequency of CCR5*D32 homozygotes was observed in patients with HCV infection. Others have countered that this observation might be the result of the groups compared. 37, [57] [58] [59] [60] Studies have addressed genetic variation in the regulatory regions of immunomodulatory cytokine genes as well. Several studies have focused on genes such as interleukin-10 (IL10) and tumour necrosis factor (TNF), and have observed no association with respect to TNF-a and HCV susceptibility, 46, 24, 61 but one study observed an association with the IL10 G/G genotype and chronic infection when compared to healthy controls (OR ¼ 2.75 (adjusted for age and sex); 95% CI: 1.01-7.50; P ¼ 0.048).46 Associations were observed between the Haptoglobin1-1 allele and risk for HCV infection (Po0.001). While there are no estimates of the relative contribution of MHC vs non-MHC genes to clinical outcome in HCV, in studies of other diseases, such as hepatitis B, the contributions appear to be well balanced or supportive of a greater effect from non-MHC genes. 62 Response to anti-HCV therapies A total of 32 studies addressed the potential role of genetics in the response to interferon therapy or variations in viral load. 16, 24, 27, 37, 39, [46] [47] [48] [49] Unlike studies of susceptibility to HCV, the majority of studies have concerned regions outside the MHC, with an emphasis on single-nucleotide polymorphisms (SNPs). Three main outcomes are commonly examined in studies of the response to anti-HCV therapies: (1) Sustained responsenow commonly defined virologically as having undetectable serum HCV-RNA levels at 6 months after the discontinuation of treatment. Older studies have defined response biochemically as a normalisation of liver enzymes, which was at one time, the main treatment end point; (2) Initial response-this is a disappearance in serum levels of HCV-RNA at the end of the initial phase of treatment-commonly 12 weeks after the inception of the regimen. A portion of these individuals who have achieved initial response may also experience a virological relapsed responders later on, so they are not true responders. (3) Nonresponders-these are individuals who have detectable viraemia at week 12 of therapy. They are distinct from initial responders because they never achieved any sort of major virological decline to undetectable levels during the initial course (first 12 weeks) of therapy.
Relapse responders represent an intermediate phenotype between sustained responders and nonresponders. As a result, they may be classified independently as their own phenotype in some studies, included with nonresponders in some studies, or included with sustained responders in other studies to create an 'initial response' phenotype that includes all individuals with declines in HCV-RNA levels during the initial 12 weeks of therapy. Additionally, it is worth noting that some studies deal with interferon monotherapy, while others deal with interferon and ribavirin combination therapy. Studies have not yet emerged involving the newer pegylated interferons, both as monotherapy or in combination with ribavirin. Thursz, 1999
Minton, 1998
Cramp, 1998 Unlike the replicated associations of DQB1*0301 and DRB1*11 with self-limiting infection, clear and replicated associations have not been observed with alleles of the MHC and therapeutic outcome. In fact, there have been some contradicting observations. Kikuchi et al 73 observed that the HLA-DR4 group was associated with nonresponse. In contrast, Sim et al 82 observed the DRB1*0404 allele (a subset of the DR4 sero-group) to be correlated with response. One major explanation for the observed differences between these two studies is that the populations were different with respect to race, and gene frequencies may vary greatly from race to race. While the Kikuchi study examined Japanese patients, the Sim paper studied Caucasians from Canada. 73, 82 Both studies defined response based on biochemical parameters. Geographic variations in viral genotype also exist, with genotype 1 predominating in North American countries such as Canada, and genotypes 2 and 6, in addition to genotype 1, also existing in parts of eastern Asia, and it is possible that viral genotypic differences may mask host genetic associations. Kikuchi et al 73 examined differences in HCV genotype, while Sim et al 82 did not. Contradictory associations have also been observed with respect to association studies of cytokine gene polymorphisms and the response to interferon-based therapies for HCV. Because of the important roles of IL10 in the immune response, several studies have examined the role of functional polymorphisms in this gene with initial response and sustained response. In a small-scale study, an Australian group looked at SNPs and the resulting haplotypes that these alleles form and correlated them with initial response to interferon monotherapy. 67 They observed the IL10 À592A and À819 T alleles to be correlated with initial response (OR ¼ 5.0, 95% CI: 1.4-9.0; P ¼ 0.01). In another study employing patients treated with interferon þ ribavirin combination therapy, Yee et al 84 found that carriage of the À592A or À819T alleles, and the corresponding extended haplotype as defined by the IL10R allele À591A þ À819T þ À1082A þ À2763C þ À3575T þ 108 bp IL10R, conferred an advantage for sustained response to therapy (OR ¼ 2.2, P ¼ 0.016 for the individual SNPs and OR ¼ 2.65, P ¼ 0.01 for the haplotype). 84 Homozygosity for the À592A or À819 T alleles, or the homozygosity for the corresponding extended haplotype showed a very strong association with sustained response (OR ¼ 16.6, P ¼ 0.013 for the homozygous genotypes and OR ¼ 13.7, P ¼ 0.025 for the haplotype). Another study failed to confirm such an association between IL10 polymorphisms and the response to therapy. 24 A recent paper suggested that the production of IL10 is probably more complicated than originally thought, as environmental factors may work along with genetic factors to play a role in affecting IL10 expression. 86 This complexity underlying IL10 expression may explain some of the discrepancies between these studies. A couple of studies have examined the role of TNF variants and the response to therapy. Both studies did not detect a relationship between polymorphisms in this gene and response to therapy. 81, 84 One study examined the role of polymorphisms in genes involved with the interferon response pathways. The Japanese group examined the role of polymorphisms in the MxA gene and response to interferon monotherapy in a Japanese population and observed the À88MxA-(G/ G) genotype to be correlated with nonresponse and the À123MxA-(C/C) genotype to be correlated with nonresponse.
71,72
Studies of HCV progression or severity of disease A total of 44 studies were found to address the topic of host genetics and HCV progression, severity or activity of disease, and have largely been inconsistent. 16, 18, 27, 29, 32, 34, 37, 39, 47, [68] [69] [70] 80, There is a trend with DRB1*11 alleles and less severe liver disease. Asti observed the combination of DRB1*0901 and the TNF-B1 homozygous genotype associated with inactive HCV, while DRB1*0405 along with the TNF-B2 homozygous genotype associated with active HCV. The functional significance of these alleles is not currently known. The definition of 'less severe disease' in these studies also varies greatly, ranging from biochemical (ie, ALT levels) to histological definitions. Future studies are needed to refine these observations. Most of the studies reviewed did not adjust for potential environmental confounders, such as alcohol use. Future studies will need to examine specific markers in conjunction with other potential genes (epigenetic interactions), environmental, as well as viral confounders.
Nine studies directly examined the role of HFE gene variants and the progression of liver disease. 80, 92, 93, 97, 98, 102, 109, 111, 101 Two major polymorphisms are recognised in the literature: Cys282Tyr and His63Asp (often abbreviated as C282Y and H63D, respectively, in single-letter amino-acid notation). Of these two polymorphisms, the Cys282Tyr has been of greater interest. Some individuals with this variant have slightly elevated hepatic iron content. 118, 119 Phenotypic penetrance of the variant genotypes is not 100%. 119 Given the observation that a number of individuals with chronic HCV infection have excess hepatic iron, 120 some investigators have examined whether possession of these variants is associated with advanced liver disease. The results of these studies have been discrepant, 119, 121 with four studies suggesting an association between possession of HFE variants and increased fibrosis or cirrhosis, 80, 92, 101, 109 and the other studies suggesting that there are no associations. Methodological differences may account for these differing observations. For example, studies employed different scoring systems for histological fibrosis. Some studies conducted categorical analyses, while others compared averages of these semiquantitative categories. Studies were generally cross-sectional in design and correlations were conducted with respect to the stage of fibrosis, irrespective of the duration of HCV infection.
Studies of extrahepatic manifestations
A total of 16 studies addressed correlations between host genetics and the occurrence of extrahepatic manifestations in HCV. 47, 92, 97, 98, 109, [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] Two studies observed an association between DRB1*11 and the presence of cryoglobulins (OR not reported in Amaroso study; OR ¼ 3.4 in Cacoub study). 122, 123 Both studies examined Italian populations. Two other studies conducted in ethnically dissimilar populations found an association between the class II DR3 allele with the presence of cryoglobulins (RR ¼ 6.14 and 3.7, respectively). 127, 132 Hwang et al 127 studied Chinese patients, while Lenzi et al 132 studied Italians. Lenzi et al also examined class I loci as well and found an association with B8 and the presence of cryoglobulins. Linkage between B8 and DR3 is quite strong, and this haplotype has been linked with several autoimmune diseases including autoimmune hepatitis type I, primary biliary cirrhosis and rheumatoid arthritis. [133] [134] [135] [136] [137] A few studies have also addressed the potential role of the HFE gene variants (Cys282Tyr or His63Asp polymorphisms) and iron levels. No consistent observations with respect to this locus have been observed, with several studies reporting no association between this variant and increased iron, 93, 97, 131 and another study reporting an association between this locus and higher mean ferritin levels. 109 Differences in study design-for example the definition of iron (ie, serum ferritin levels vs iron stains of liver biopsies)-may play a major role in these differences. Some studies employed use of the 5-point METVIR scoring system for liver fibrosis while others used the 7-point Knodell histological activity index. In addition, use of these semiquantitative scoring systems is accompanied by a degree of interobserver variation. These differences make the use of metaanalyses to pool data from these studies difficult.
Conclusions
This paper attempts to highlight a few of the main trends in the literature on host genetic determinants of HCV outcome. The most interesting association is with the class II alleles, DQB1*0301 and DRB1*11, and selflimiting HCV infection. With respect to the response to therapy, discrepant findings have been observed. There is an apparent correlation between alleles in the DR5 sero-group with milder liver disease. Two studies have shown a correlation between the DRB1*11 allele and the presence of cryoglobulins, while two other studies have shown correlations between the DR3 allele and the formation of cryoglobulins.
Reproducibility is essential in this field. Unfortunately, there tends to be a bias in the reported literature towards the publication of positive results. Another concern is that demonstration of an association with an allele, even after confirmation, does not necessarily imply that the allele is functionally responsible for changes in disease susceptibility or resistance. Allelic variants are carried on long segments of DNA, which are likely to contain other polymorphisms and are inherited as haplotypes. The patterns of linkage disequilibrium between polymorphic loci are complex. Therefore, comprehensive investigation is required to identify causative variants from those that are associated through linkage disequilibrium.
There has been a tendency in recent years to dismiss the potential contribution of genetic association studies to the scientific literature due to the lack of data on the functional effects of many genotypic variants that have been studied. It is important to bear in mind that the understanding of genetics in health and disease consists of several different parts: (1) the identification of new polymorphisms, (2) the association of these polymorphisms with disease outcomes, and (3) the understanding of the functional effects of these variants. These three factors may not necessarily be completed at the same time, and the importance of studies addressing only one or two of these aspects should not be dismissed. With the human genome project it is likely that the identification of new polymorphisms and the association of new polymorphisms with disease outcomes will far exceed the speed at which functional studies are conducted, and many negative findings will be observed. Given the importance of replication in this field, it is important that all of the evidence be considered, regardless of whether the associations are positive or negative. Functional genomics, such as the use of microarrays and proteomics, may provide further insight into important pathways as well as functional parameters of the host response to HCV and complement genetic association studies. 138, 139 While there are some consistent observations (ie, DQB1*0301 and self-limiting infection), there are more inconsistent observations. Several factors may account for these inconsistencies. First, different populations were studied and gene frequencies vary across races. It is quite plausible that one ethnic group may have the preferential use of different allele(s) in viral eradication than those in other ethnic groups. Proper consideration of racial heterogeneity will have to be taken into account in future studies. [140] [141] [142] Confounding and/or interactions from other genetic, environmental/behavioural and/or viral factors may also contribute to HCV outcome. Many of the studies were conducted on relatively small samples. Smaller samples decrease the power of the study (likelihood of detecting a difference between groups, assuming that a true difference exists) as well as the precision of the measurements of association. 143 The issue of sample size is even more critical in studies concerning the MHC, which is known to be one of the most genetically diverse regions of the human genome. Lack of an association may not mean that associations do not exist; rather, they may be a reflection of an underpowered study's inability to detect meaningful differences. Future studies will have to be sufficiently powered to accommodate not only adjustment for potential confounders but the possibility of interactions of putative genes with other factors. Finally, proper epidemiologic study design will also be important. 54, 144 In conclusion, there is a need for large, well-powered and well-designed genetic epidemiologic studies to examine host genetic determinants of HCV outcome. Hopefully advances in the field will help elucidate potential genetic and physiological pathways that may serve as drug targets and facilitate the development of more effective therapies. 145 While much work has been conducted in the field, its further success will likely involve an integrated approach that involves epidemiology, molecular genetics, functional biology and clinical medicine.
Methods
Search strategy A series of subject and keyword searches were conducted first using the 1966-1 June 2003 Medline and then repeated using the 1980-1 June 2003 EMBASE database. First, 'hepatitis C' was used as a subject heading, with the subgroup 'genetics'. Next, a series of keyword searches were used to first identify articles related to 'hepatitis C' and then combined with the following keywords using the 'and' statement: 'polymorphism, HLA, MHC and genetics'. In addition, the citations of the bibliographies of these articles were reviewed for additional references. Finally, the search was repeated in the 1980-1 June 2003 PubMed database. Articles were restricted to those in the English language. All articles were evaluated for study design, technical aspects such as genotyping methods (serological vs molecular) and statistical rigour.
Meta-analysis
All meta-analyses were conducted using the STATA s software (College Station, TX, USA). Forest plots, tests of heterogeneity and pooled estimates (with random effects) with weighted adjustments for sample size were calculated using this software. 55 
